Stay updated with breaking news from Breakthrough Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN TORONTO, Jan. 24, 2024 -- REVIVE...
Ensysce Biosciences Inc (NASDAQ:ENSC) received an FDA Breakthrough Therapy Designation (BTD) for PF614-MPAR, a next-generation opioid. BTD has been granted to fewer than 300 drugs. It is designed to expedite the development and reviewing of drugs intended to treat a serious condition where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapies. PF614-MPAR is designed to provide optimal pain relief at prescribed doses yet limit accid
The FDA has granted Breakthrough Therapy designation to PF614-MPAR, an oral opioid analgesic designed with overdose protection.
Exceeded originally target enrollment with n=74 Last patient, last visit expected in approximately six weeks; data to follow shortly thereafterPositive...
State-level psychedelics policy reform is moving fast throughout the U.S. Here’s a recap from our previous update and as of Jan. 18, 2024: